Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome

Ilya Reznik, Baruch Spivak, Rima Melman, Moshe Kotler, Abraham Weizman, Roberto Mester

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: Antipsychotic medication continues to be an essential component in the treatment of schizophrenia. Neuroleptic malignant syndrome (NMS) is one of the most serious complications of neuroleptic treatment and the optimal therapeutic aftercare regimen for patients is unclear. Also, it is not clear if low-dose neuroleptic maintenance in such patients is safe and efficient enough over time. METHOD: We present a case of a 56-year-old woman suffering from schizoaffective disorder, who was successfully treated with a low dosage of clozapine for 6.5 years following a NMS episode. RESULT: To the best of our knowledge this is the first report of such a long-term beneficial use of low-dose clozapine in a patient who previously underwent such a serious complication. CONCLUSION: Large-scale studies are needed to substantiate this observation.

Original languageEnglish
Pages (from-to)121-123
Number of pages3
JournalInternational Journal of Psychiatry in Clinical Practice
Volume6
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • Aftercare treatment
  • Antipsychotics maintenance
  • Clozapine
  • Mental retardation
  • Neuroleptic malignant syndrome (NMS)
  • Schizoaffective disorder

Fingerprint

Dive into the research topics of 'Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome'. Together they form a unique fingerprint.

Cite this